{
    "clinical_study": {
        "@rank": "134499", 
        "arm_group": [
            {
                "arm_group_label": "Arm A: Cetuximab + Afatinib", 
                "arm_group_type": "Experimental", 
                "description": "Afatinib 40 mg daily Cetuximab 500 mg/m2 every 2 weeks until progression"
            }, 
            {
                "arm_group_label": "Arm B : Cetuximab alone", 
                "arm_group_type": "Active Comparator", 
                "description": "Cetuximab 500mg/m2 every 2 weeks until progression After progression: Cetuximab 500mg/m2 + Afatinib 40 mg per day until progression"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multicentric, phase II and open label study.75 patients are expected to be\n      randomized in 35 centers. The main objective is to assess the efficacy and safety of\n      Afatinib -cetuximab combo versus cetuximab alone in treatment of patients with refractory\n      wtKRAS metastatic colorectal cancer."
        }, 
        "brief_title": "Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer", 
        "completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Patients who will sign the inform consent will be enrolled into one of two groups. Group A\n      will receive Afatinib ( 40mg per day)  and Cetuximab (500mg/m2)every two weeks until\n      progression. Group B will receive Cetuximab (500mg/m2) alone every two weeks until\n      progression and after progression,patients from group B will receive afatinib (group A\n      treatment) until progression. The criteria for evaluation will be tumor response and\n      progression documented by CT scan and according to RECIST criteria version 1.1.\n\n      Patient will also sign a inform consent before participating in biological study. The aim of\n      this translational study is to collect tumor and blood sample in order to determine, the\n      biological factors which are predictive of the response to treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Metastatic colorectal cancer expressing the wtKRAS status\n\n          2. No previous EGFR targeted therapy.\n\n          3. Must have failed a prior regimen containing irinotecan for metastatic disease and a\n             prior regimen containing oxaliplatin for metastatic disease\n\n          4. Must have previously received a thymidylate synthase inhibitor (eg, fluorouracil,\n             capecitabine, raltitrexed, or fluorouracil-uracil) at any point for treatment of\n             colorectal cancer (CRC)\n\n          5. Life expectancy of at least 3 months.\n\n          6. Patient with ECOG \u2264 1\n\n          7. Patients aged \u2265 18.\n\n          8. Patient with measurable lesions according to RECIST criteria (version 1.1) with\n             spiral CT scan and defined as \u2265 10 mm in longest diameter and 2X the slice thickness\n             for extra nodal lesions and/or > 15 mm in short axis diameter for nodal lesions\n\n          9. Patient able to receive adequate oral nutrition of \u2265 1500 calories per day and free\n             of significant nausea and vomiting\n\n         10. Patient with adequate organ function:\n\n               -  Absolute neutrophil count (ANC) \u2265 1.5 x 109/L\n\n               -  Haemoglobin \u2265 9 g/dL\n\n               -  Platelets (PTL) \u2265 100 x 109/L\n\n               -  AST/ALT \u2264  3 x ULN (\u2264 5 x ULN in case of liver metastases)\n\n               -  GammaGT < 3 x ULN (< 5 x ULN in case of liver involvement)\n\n               -  Bilirubin \u2264 1.5 x ULN\n\n               -  Creatinine clearance \u2265 50 mL/min (Cockcroft and Gault formula)\n\n         11. Adequate contraception if applicable.\n\n         12. Ability to take oral medication in the opinion of the investigator\n\n         13. Patient able and willing to comply with study procedures as per protocol\n\n         14. Patient able to understand and willing to sign and date the written voluntary\n             informed consent form at screening visit prior to any protocol-specific procedures\n\n         15. Patient affiliated to a social security regimen\n\n        Exclusion Criteria:\n\n          1. Previous EGFR targeted therapy.\n\n          2. Mutant KRAS status\n\n          3. Prior severe reaction to a monoclonal antibody\n\n          4. No heart failure or coronary heart disease symptoms Clinically relevant\n             cardiovascular abnormalities, as judged by the investigator, such as, but not limited\n             to, uncontrolled hypertension, congestive heart failure NYHA classification > III,\n             unstable angina, myocardial infarction within six months prior to randomisation, or\n             poorly controlled arrhythmia\n\n          5. Cardiac left ventricular dysfunction with resting ejection fraction of less than\n             institutional lower limit of normal (if no lower limit of normal is defined in the\n             institution, the lower limit is 50%)\n\n          6. Symptomatic brain metastases requiring treatment\n\n          7. Major surgery within 28 days or minor surgery within 14 days of the start of the\n             study treatment\n\n          8. Radiotherapy less than two weeks prior to the start of the study treatment\n\n          9. Systemic chemotherapy, hormonal therapy, immunotherapy \u2264 21 days before study\n             treatment\n\n         10. No major comorbidity that may preclude the delivery of treatment or active infection\n             (HIV or chronic hepatitis B or C) or uncontrolled diabetes.\n\n         11. Concomitant occurrence of another cancer, or history of cancer within the past five\n             years except in situ carcinoma of the cervix treated or basal cell carcinoma or\n             squamous cell carcinoma.\n\n         12. Known pre-existing interstitial lung disease\n\n         13. Significant or recent acute gastrointestinal disorders with diarrhea as a major\n             symptom e.g., Crohn's disease, malabsorption, or CTCAE grade >2 diarrhea of any\n             etiology\n\n         14. Pregnant woman or lactating woman.\n\n         15. Persons deprived of liberty or under guardianship.\n\n         16. Psychological, familial, sociological or geographical condition potentially hampering\n             compliance with the study protocol and follow-up schedule.\n\n         17. Previous history of keratitis, ulcerative keratitis or severe dry eye."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "75", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01919879", 
            "org_study_id": "UCGI 25"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm A: Cetuximab + Afatinib", 
                    "Arm B : Cetuximab alone"
                ], 
                "description": "Afatinib taken orally, cetuximab administered intravenously", 
                "intervention_name": "Cetuximab + Afatinib", 
                "intervention_type": "Drug", 
                "other_name": "Erbitux"
            }, 
            {
                "arm_group_label": "Arm B : Cetuximab alone", 
                "description": "Cetuximab administered intravenously", 
                "intervention_name": "Cetuximab", 
                "intervention_type": "Drug", 
                "other_name": "Erbitux"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Cetuximab"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Chemotherapy refractory", 
            "wtKRAS metastatic colorectal cancer", 
            "cross over"
        ], 
        "lastchanged_date": "August 6, 2013", 
        "location": {
            "contact": {
                "email": "jaafar.bennouna@ico.unicancer.fr", 
                "last_name": "Jaafar BENNOUNA, Dr"
            }, 
            "contact_backup": {
                "email": "helene.senellart@ico.unicancer.fr", 
                "last_name": "H\u00e9l\u00e8ne SENELLART, Dr", 
                "phone": "+ 33 2 40 67 99 78"
            }, 
            "facility": {
                "address": {
                    "city": "Nantes", 
                    "country": "France", 
                    "zip": "44805"
                }, 
                "name": "Institute de Canc\u00e9rologie de la Loire"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicentric Randomized Phase II Trial Evaluating Dual Targeting of EGFR Using the Combination of Cetuximab and Afatinib Versus Cetuximab Alone in Patients With Chemotherapy Refractory wtKRAS Metastatic Colorectal Cancer", 
        "overall_contact": {
            "email": "t-stanbury@unicancer.fr", 
            "last_name": "Trevor STANBURY", 
            "phone": "+ 33 (1) 44235567"
        }, 
        "overall_official": [
            {
                "affiliation": "Centre Ren\u00e9 Gauducheau- Nantes Saint herbelain", 
                "last_name": "Helene SENELLART, Dr", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Centre Eug\u00e8ne Marquis-Rennes", 
                "last_name": "Evelyne BOUCHER, Dr", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Centre Antoine Lacassagne-Nice", 
                "last_name": "Eric FRANCOIS, Dr", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Centre Val d'Aurel-Paul Lamarque-Montpellier", 
                "last_name": "Emmanuelle SAMALIN SCALZI, Dr", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Centre Paul Strauss-Strasbourg", 
                "last_name": "Meher BEN ABDELGHANI, Dr", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Centre Oscar Lambret_Lille", 
                "last_name": "Antoine ADENIS, Pr", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Centre L\u00e9on B\u00e9rard-Lyon", 
                "last_name": "Christelle DE LA FOUCHARDIERE, Dr", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Centre Georges Leclerc-Dijon", 
                "last_name": "Fran\u00e7ois GHIRENGHELLI, Dr", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Centre Jean Godinot-Reims", 
                "last_name": "Olivier DUBROEUCQ, Dr", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hopital Rene Huguenin_Intitut Curie_Paris", 
                "last_name": "Emmanuelle MITRY, Dr", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "H\u00f4pital Jean Minjoz-Besa\u00e7on", 
                "last_name": "Christophe BORG, Pr", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Institut Bergoni\u00e9-Bordeaux", 
                "last_name": "Yves BOUCARN, Dr", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Centre Hospitalier de Belfort-Montbelliard", 
                "last_name": "Christophe BORG, Pr", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Centre Hospitalier Lyon Sud-Pierre Benite", 
                "last_name": "Marion CHAUVENET, Dr", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The progression rate is defined as percentage of patients without progression at 6 months after observation of all patients at 6 months", 
            "measure": "Non progression rate at 6 months", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01919879"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Overall response rate is defined as percentage of subjects with a confirmed complete or partial response as per RECIST V1.1 criteria", 
                "measure": "Overall response rate (OR)", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "It is define as the time of from randomization to date of first documented  progression or any cause of death", 
                "measure": "Progression free survival", 
                "safety_issue": "Yes", 
                "time_frame": "until progression or death, expected average approximately 4 months"
            }, 
            {
                "description": "Overall and specific survival is defined from time of randomization to the date of documented death", 
                "measure": "Overall and specific survival", 
                "safety_issue": "Yes", 
                "time_frame": "until death, on average approximately 14 months"
            }, 
            {
                "description": "EORTC QLQ-C30 and QLQ-CR29 are questionnaires developed to assess the quality of life of cancer patients", 
                "measure": "Quality of life", 
                "safety_issue": "Yes", 
                "time_frame": "During treatment, on average approximately 4 months"
            }, 
            {
                "description": "Safety of the study treatment will be assessed on occurrence of Adverse Events (AEs)", 
                "measure": "Tolerance of the treatment", 
                "safety_issue": "Yes", 
                "time_frame": "until progression, expected approximately 4 months"
            }
        ], 
        "source": "UNICANCER", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "UNICANCER", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}